As global markets brace for volatility, Malaysia’s financial stability, Nvidia’s tech struggles, and China’s trade freeze take center stage—while Alps Global advances its biotech ambitions.

Malaysia:
The ringgit ended Tuesday nearly flat against the US dollar, closing at 4.4100/4155. With high-stakes trade talks between the US and Japan scheduled for Thursday, markets remain cautious. Analysts say Japan’s treatment may signal the US approach to tariff diplomacy going forward. Meanwhile, the ringgit posted mixed results against global and ASEAN currencies, reflecting broader uncertainty.

International:
Nvidia announced a US$5.5 billion charge due to new export restrictions on its H20 AI chips destined for China. The U.S. now requires licenses for such shipments, citing national security concerns. The impact was immediate—Nvidia’s stock tumbled over 6%, with ripple effects seen in AMD and Broadcom. These restrictions underscore growing tensions in the global tech supply chain.

Asia:
At the Canton Fair in Guangzhou, Chinese exporters reported a collapse in US orders due to the new 145% tariffs. Firms heavily reliant on American clients are struggling, with many unable to redirect business fast enough. Attendance from the US and Europe dropped significantly, pointing to a broader slowdown in trade momentum.

Alps Global Holding Berhad:
Despite a year since announcing the biotech hub collaboration with Johor Corporation, Alps Global Holding remains fully committed to the RM980 million project. Positioned within the Ibrahim Technopolis in Johor, the hub will focus on vaccines, genomics, regenerative medicine, and medical tourism. Phase 1 infrastructure is already in motion, and Alps is aligned with national goals under NIMP2030 and NETR, driving biotech innovation in Malaysia.